Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last 90.45 INR
Change Today 0.00 / 0.00%
Volume 0.0
As of 7:06 AM 08/28/15 All times are local (Market data is delayed by at least 15 minutes).

marksans pharma ltd (MRKS) Snapshot

Open
92.50
Previous Close
90.45
Day High
94.40
Day Low
89.00
52 Week High
08/10/15 - 115.00
52 Week Low
09/3/14 - 48.30
Market Cap
37.0B
Average Volume 10 Days
5.3M
EPS TTM
2.74
Shares Outstanding
409.3M
EX-Date
--
P/E TM
33.0x
Dividend
0.12
Dividend Yield
0.11%
Current Stock Chart for MARKSANS PHARMA LTD (MRKS)

Related News

No related news articles were found.

marksans pharma ltd (MRKS) Related Businessweek News

No Related Businessweek News Found

marksans pharma ltd (MRKS) Details

Marksans Pharma Limited, together with its subsidiaries, is engaged in the research, manufacture, and marketing of generic pharmaceutical formulations worldwide. Its product portfolio covers primary therapeutic segments of CVS, analgesics, decongestants, gastrointestinal, cardiovascular, anti-diabetics, central nervous system, oncology, anti-allergic drugs, and others. It also manufactures and distributes over-the-counter pharmaceutical products in the areas of cough and cold remedies, galenicals, vitamins, palliative and healthcare items, oils, antiseptics, and disinfectants; and offers contract research and manufacturing services to global pharmaceutical companies. Marksans Pharma Limited is headquartered in Mumbai, India.

marksans pharma ltd (MRKS) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

marksans pharma ltd (MRKS) Key Developments

Marksans Pharma Ltd. Announces Unaudited Standalone and Consolidated Earnings Results for Quarter Ended June 30, 2015

Marksans Pharma Ltd. announced unaudited standalone and consolidated earnings results for quarter ended June 30, 2015. For the quarter, the company reported consolidated net sales/income from operations of INR 2,101.59 million, profit from operations before other income, finance costs and exceptional items of INR 478.83 million, profit from ordinary activities before tax of INR 449.02 million, net profit of INR 323.36 million or INR 0.77 basic and diluted per share, compared to the net sales/income from operations of INR 2,023.95 million, profit from operations before other income, finance costs and exceptional items of INR 387.59 million, profit from ordinary activities before tax of INR 352.21 million, net profit of INR 259.18 million or INR 0.66 basic and diluted per share, for the same quarter a year ago. EBITDA grew by 22.45% to INR 524.06 million. For the quarter, the company reported standalone net sales/income from operations of INR 1,023.23 million, profit from operations before other income, finance costs and exceptional items of INR 365.08 million, profit from ordinary activities before tax of INR 341.27 million, net profit of INR 238.77 million or INR 0.58 basic and diluted per share, compared to the net sales/income from operations of INR 1,006.65 million, profit from operations before other income, finance costs and exceptional items of INR 275.59 million, profit from ordinary activities before tax of INR 250.15 million, net profit of INR 182.64 million or INR 0.47 basic and diluted per share, for the same quarter a year ago.

Marksans Pharma Ltd., Board Meeting, Aug 08, 2015

Marksans Pharma Ltd., Board Meeting, Aug 08, 2015. Agenda: To approve unaudited financial results of the company for the quarter ended June 30, 2015.

Marksans Pharma Ltd. to Report Q1, 2016 Results on Aug 08, 2015

Marksans Pharma Ltd. announced that they will report Q1, 2016 results on Aug 08, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
MRKS:IN 90.45 INR 0.00

MRKS Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for MRKS.
View Industry Companies
 

Industry Analysis

MRKS

Industry Average

Valuation MRKS Industry Range
Price/Earnings 31.3x
Price/Sales 4.4x
Price/Book 9.7x
Price/Cash Flow 27.0x
TEV/Sales 4.0x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact MARKSANS PHARMA LTD, please visit www.marksanspharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.